{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:17:07Z","timestamp":1789510627250,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ijrobp.2016.12.018","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T15:19:11Z","timestamp":1482160751000},"page":"995-1001","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["A Phase 1\/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524)"],"prefix":"10.1016","volume":"97","author":[{"given":"M. Dror","family":"Michaelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huong T.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas M.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin","family":"Lee-Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory P.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Vuky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Jeffrey","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Souhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Shipley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2016.12.018_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0360-3016(93)90306-G","article-title":"Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12","volume":"25","author":"Tester","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.1996.14.1.119","article-title":"Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802","volume":"14","author":"Tester","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib3","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib4","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0022-5347(01)62379-6","article-title":"A phase I\/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer","volume":"160","author":"Zietman","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib5","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"Kaufman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib6","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results","volume":"20","author":"Rodel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"Mitin","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1464-410X.2012.11762.x","article-title":"Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): A review of the literature and a practical approach to therapy","volume":"112","author":"Smith","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2013.11.016","article-title":"Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: Long-term results of a phase 1 trial","volume":"88","author":"Azria","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijrobp.2013.11.005","article-title":"Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer","volume":"88","author":"Turgeon","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0360-3016(97)00579-8","article-title":"Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer","volume":"40","author":"Sauer","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib12","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","article-title":"Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy","volume":"73","author":"Kaufman","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.urology.2006.10.041","article-title":"Chemotherapy for bladder cancer: Treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer","volume":"69","author":"Sternberg","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib15","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib16","first-page":"1957","article-title":"Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder","volume":"7","author":"Chow","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib17","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cncr.10808","article-title":"Does HER2\/neu expression provide prognostic information in patients with advanced urothelial carcinoma?","volume":"95","author":"Gandour-Edwards","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ijc.10731","article-title":"HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications","volume":"102","author":"Kruger","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib19","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.bjc.6601245","article-title":"HER2\/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder","volume":"89","author":"Latif","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib20","doi-asserted-by":"crossref","first-page":"e27616","DOI":"10.1371\/journal.pone.0027616","article-title":"ErbB2 and NFkappaB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer","volume":"6","author":"Koga","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijrobp.2014.05.043","article-title":"Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach","volume":"90","author":"Inoue","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijrobp.2004.09.047","volume":"62","author":"Chakravarti","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"issue":"3, Suppl 1","key":"10.1016\/j.ijrobp.2016.12.018_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0360-3016(01)01849-1","article-title":"RTOG 9706: Initial report of a phase I\/II trial of bladder-conservation employing TURB, accelerated irradiation sensitized with cisplatin followed by adjuvant chemotherapy","volume":"51","author":"Hagan","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib25","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib26","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/bjc.1990.375","article-title":"Expression of c-erbB-2 protein product in bladder cancer","volume":"62","author":"Wright","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/bjc.1991.139","article-title":"Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder","volume":"63","author":"Coombs","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib28","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/1097-0142(19921115)70:10<2493::AID-CNCR2820701017>3.0.CO;2-K","article-title":"An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma","volume":"70","author":"Sato","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0022-5347(17)37212-9","article-title":"Evaluation of epidermal growth factor receptor DNA amplification and mRNA expression in bladder cancer","volume":"147","author":"Wood","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/ajcp\/101.2.166","article-title":"Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis","volume":"101","author":"Nguyen","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib31","first-page":"2440","article-title":"Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors","volume":"7","author":"Jimenez","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2016.12.018_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1092-9134(03)00083-2","article-title":"Expression of c-erbB-2 and cytokeratins 7 and 20 in urothelial carcinoma with gland-like lumina","volume":"7","author":"Fernandez-Flores","year":"2003","journal-title":"Ann Diagn Pathol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301616335921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301616335921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T14:38:06Z","timestamp":1568644686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301616335921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0360301616335921"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2016.12.018","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1\/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2016.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}